Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial
Starting soon · Not applicable
Conditions studied: Gastric (Stomach) Cancer
In brief
This study is a prospective, multicenter cluster randomized controlled trial. Additional fecal screening for high-risk SNP subtypes, in conjunction with routine Hp testing, may improve the identification of individuals at high risk for gastric cancer. Moreover, the implementation of eradication interventions in high-risk groups has the potential to significantly reduce the incidence and progression of gastric cancer.
Key facts
- Study ID
- NCT06943794
- Run by
- Fudan University
- People needed
- 4824
- Starts
- 2026-03-30
- Expected to finish
- 2030-12-30
- Last updated by the study team
- 2026-02-25
Who can join
Age: 40 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age ≥ 40 years, gender is not limited.
- Voluntary participation with signed informed consent.
- No H. pylori eradication treatment received within the past 1 month.
- Able to complete stool sample collection and related examinations as per study requirements.
- Detected as high-risk by Hp subtype test.
You may not qualify if…
- A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.
- Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.
- Severe mental illness or incapacity to participate in the study due to lack of civil behavior.
- Pregnant or breastfeeding women.
- Other conditions that the investigator deems inappropriate for participation in the study.
Where it is running
- People's Hospital of Tongling City — Tongling, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.